Erratum to: Effects of lanthanum carbonate and calcium carbonate on fibroblast growth factor 23 and hepcidin levels in chronic hemodialysis patients (Clinical and Experimental Nephrology, (2017), 21, 5, (908-916), 10.1007/s10157-016-1362-9);Effects of lanthanum carbonate and calcium carbonate on fibroblast growth factor 23 and hepcidin levels in chronic hemodialysis patients

Clinical and Experimental Nephrology

Volumn 21, Issue 5, 2017, Pages 908-916

  Chang, Yu Ming ^a   Tsai, Shih Ching ^a   Shiao, Chih Chung ^a   Liou, Hung Hsiang ^b,d   Yang, Chuan Lan ^c   Tung, Nai Yu ^c   Hsu, Kua Sui ^c   Chen, I Ling ^c   Liu, Mei Chyn ^d   Kao, Jsun Liang ^a   Jhen, Rong Na ^a   Huang, Ya Ting ^c  

^a Department Saint Mary’s Hospital Luodong ^*  (Taiwan)

^b Hsin Jen Hospital   (Taiwan)

^c Saint Mary s Hospital Luodong   (Taiwan)

^d Dialysis Center   (Taiwan)

Author keywords

FGF23; Hemodialysis; Hepcidin; Phosphate binders

Indexed keywords

ALKALINE PHOSPHATASE; C REACTIVE PROTEIN; CALCIUM CARBONATE; FETUIN A; FIBROBLAST GROWTH FACTOR 23; HEPCIDIN; LANTHANUM; LANTHANUM CARBONATE; OSTEOPONTIN; PARATHYROID HORMONE; PHOSPHATE; VITAMIN D; BIOLOGICAL MARKER; CHELATING AGENT; FIBROBLAST GROWTH FACTOR; HAMP PROTEIN, HUMAN;

ADULT; ALBUMIN BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; CALCIUM BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL OUTCOME; CONTROLLED STUDY; FEMALE; GOOD CLINICAL PRACTICE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; MALE; MIDDLE AGED; PHOSPHATE BLOOD LEVEL; PROSPECTIVE STUDY; RANDOMIZATION; ADMINISTRATION AND DOSAGE; AGED; BLOOD; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; COMPARATIVE STUDY; DOWN REGULATION; MULTICENTER STUDY; PHOSPHATE INTAKE; RANDOMIZED CONTROLLED TRIAL; TAIWAN; TIME FACTOR; TREATMENT OUTCOME;

AGED; BIOMARKERS; CALCIUM CARBONATE; CHELATING AGENTS; DOWN-REGULATION; FEMALE; FIBROBLAST GROWTH FACTORS; HEPCIDINS; HUMANS; LANTHANUM; MALE; MIDDLE AGED; PHOSPHATES; PHOSPHORUS, DIETARY; PROSPECTIVE STUDIES; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC; TAIWAN; TIME FACTORS; TREATMENT OUTCOME;

EID: 85001874923     PISSN: 13421751     EISSN: 14377799     Source Type: Journal    
DOI: 10.1007/s10157-017-1384-y     Document Type: Erratum

References (40)

1. Gutiérrez OM, Mannstadt M, Isakova T, et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med. 2008;359:584–92.
2. Gutiérrez OM, Januzzi JL, Isakova T, et al. Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Circulation. 2009;119:2545–52.
3. Mirza MA, Larsson A, Lind L, et al. Circulating fibroblast growth factor-23 is associated with vascular dysfunction in the community. Atherosclerosis. 2009;205:385–90.
4. Mirza MA, Hansen T, Johansson L, et al. Relationship between circulating FGF23 and total body atherosclerosis in the community. Nephrol Dial Transplant. 2009;24:3125–31.
5. Gonzalez-Parra E, Gonzalez-Casaus ML, Galán A, et al. Lanthanum carbonate reduces FGF 23 in chronic kidney disease stage 3 patients. Nephrol Dial Transplant. 2011;26:2567–71.
6. Isakova T, Barchi-Chung A, Enfield G, et al. Effects of diet phosphate restriction and phosphate binders on FGF23 levels in CKD. Clin J Am Soc Nephrol. 2013;8:1009–18.
7. Yilmaz MI, Sonmez A, Saglam M, et al. Comparison of calcium acetate and sevelamer on vascular function and fibroblast growth factor 23 in CKD patients: a randomized clinical trial. Am J Kidney Dis. 2012;59:177–85.
8. Oliveira RB, Cancela AL, Graciolli FG, et al. Early control of PTH and FGF23 in normophosphatemic CKD patients: a new target in CKD-MBD therapy? Clin J Am Soc Nephrol. 2010;5:286–91.
9. Soriano S, Ojeda R, Rodríguez M, et al. The effect of phosphate binders, calcium and lanthanum carbonate on FGF23 levels in chronic kidney disease patients. Clin Nephrol. 2013;80:17–22.
10. Koiwa F, Kazama JJ, Tokumoto A, et al. Sevelamer hydrochloride and calcium bi-carbonate reduce serum fibroblast growth factor 23 levels in dialysis patients. Ther Apher Dial. 2005;9:336–9.
11. Spatz C, Roe K, Lehman E, et al. Effect of a non-calcium-based phosphate binder on fibroblast growth factor 23 in chronic kidney disease. Nephron Clin Prac. 2013;123:61–6.
12. Brandenberg VM, Schlieper G, Heussen N, et al. Serological cadiovascular and mortality risk predictors in dialysis patients receiving sevelamer: a prospective study. Nephrol Dial Transplant. 2010;25:2672–9.
13. Shigematsu T. Negi S; COLC Research Group. Combined therapy with lanthanum carbonate and calcium carbonate for hyperphosphatemia decreases serum FGF-23 level independently of calcium and PTH (COLC Study). Nephrol Dial Transplant. 2012;27:1050–4.
14. Cancela AL, Oliveira RB, Graciolli FG, et al. Fibroblast growth factor 23 in hemodialysis patients: effects of phosphate binder, calcitriol and calcium concentration in the dialysate. Nephron Clin Pract. 2011;117:c74–82.
15. Toida T, Fukudome K, Fujimoto S, et al. Effect of lanthanum carbonate vs. calcium carbonate on serum calcium in hemodialysis patients: a crossover study. Clin Nephrol. 2012;78:216–23.
16. Yusuf AA, Weinhandl ED, St Peter WL. Comparative effectiveness of calcium acetate and sevelamer on clinical outcomes in elderly hemodialysis patients enrolled in Medicare part D. Am J Kidney Dis. 2014;64:95–103.
17. Jamal SA, Vandermeer B, Raggi P, et al. Effect of calcium-based versus non-calcium-based phosphate binders on mortality in patients with chronic kidney disease: an updated systematic review and meta-analysis. Lancet. 2013;382:1268–77.
18. Ganz T. Molecular control of iron transport. J Am Soc Nephrol. 2007;18:394–400.
19. Young B, Zaritsky J. Hepcidin for clinicians. Clin J Am Soc Nephrol. 2009;4:1384–7.
20. Ganz T. Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation. Blood. 2003;102:783–8.
21. Carvalho C, Isakova T, Collerone G, et al. Hepcidin and disordered mineral metabolism in chronic kidney disease. Clin Nephrol. 2011;76:90–8.
22. Samouilidou E, Pantelias K, Petras D, et al. Serum hepcidin levels are associated with serum triglycerides and interleukin-6 concentrations in patients with end-stage renal disease. Ther Apher Dial. 2014;18:279–83.
23. Shimada T, Yamazaki Y, Takahashi M, et al. Vitamin D receptor-independent FGF23 actions in regulating phosphate and vitamin D metabolism. Am J Physiol Renal Physiol. 2005;289:F1088–95.
24. Kobayashi K, Imanishi Y, Miyauchi A, et al. Regulation of plasma fibroblast growth factor 23 by calcium in primary hyperparathyroidism. Eur J Endocrinol. 2006;154:93–9.
25. David V, Dai B, Martin A, et al. Calcium regulates FGF-23 expression in bone. Endocrinology. 2013;154:4469–82.
26. Rodriquez-Ortiz ME, Lopez I, Muñoz-Castañeda JR, et al. Calcium deficiency reduces circulating levels of FGF23. J Am Soc Nephrol. 2012;23:1190–7.
27. Caglar K, Yilmaz MI, Saglam M, et al. Short-term treatment with sevelamer increases serum fetuin-A concentration and improves endothelial dysfunction in chronic kidney disease stage 4 patients. Clin J Am Soc Nephrol. 2008;3:61–8.
28. Zhou YB, Jin SJ, Cai Y, et al. Lanthanum acetate inhibits vascular calcification induced by vitamin D3 plus nicotine in rats. Exp Biol Med. 2009;234:908–17.
29. El-Abbadi MM, Pai AS, Leaf EM, et al. Phosphate feeding induces arterial medial calcification in uremic mice: role of serum phosphorus, fibroblast growth factor-23, and osteopontin. Kidney Int. 2009;75:1297–307.
30. D’Haese PC, Spasovski GB, Sikole A, et al. A multicenter study on the effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease in dialysis patients. Kidney Int. 2003;63(Suppl 85):S73–8.
31. Manabe R, Fukami K, Ando R, et al. Effects of switching from calcium carbonate to lanthanum carbonate on bone mineral metabolism in hemodialysis patients. Ther Apher Dial. 2013;17(Suppl 1):35–40.
32. Guo F, Guo X, Xie A, et al. The suppressive effects of lanthanum on the production of inflammatory mediators in mice challenged by LPS. Biol Trace Elem Res. 2011;142:693–703.
33. Navarro-González JF, Mora-Fernández C, Muros M, et al. Mineral metabolism and inflammation in chronic kidney disease patients: a cross-sectional study. Clin J Am Soc Nephrol. 2009;4:1646–54.
34. Nicolas G, Bennoun M, Devaux I, et al. Lack of hepcidin gene expression and severe tissue iron overload in upstream stimulatory factor 2 (USF2) knockout mice. Proc Natl Acad Sci USA. 2001;98:8780–5.
35. Lesbordes-Brion JC, Viatte L, Bennoun M, et al. Targeted disruption of the hepcidin 1 gene results in severe hemochromatosis. Blood. 2006;108:1402–5.
36. Takeda Y, Komaba H, Goto S, et al. Effect of intravenous saccharated ferric oxide on serum FGF23 and mineral metabolism in hemodialysis patients. Am J Nephrol. 2011;33:421–6.
37. Braithwaite V, Prentice AM, Doherty C, et al. FGF23 is correlated with iron status but not with inflammation and decreases after iron supplementation: a supplementation study. Int J Pediatr Endocrinol. 2012;2012:27.
38. Deger SM, Erten Y, Pasaoglu OT, et al. The effects of iron on FGF23-mediated Ca-P metabolism in CKD patients. Clin Exp Nephrol. 2013;17:416–23.
39. Gravesen E, Hofman-Bang J, Mace ML, et al. High dose intravenous iron, mineral homeostasis and intact FGF23 in normal and uremic rats. BMC Nephrol. 2013;14:281.
40. Lin HH, Liou HH, Wu MS, et al. Long-term sevelamer treatment lowers serum fibroblast growth factor 23 accompanied with increasing serum Klotho levels in chronic haemodialysis patients. Nephrology. 2014;19:672–8.